July 30, 2014
Drug makers are increasingly shifting to the development of anticancer agents after a cascade of patent expirations spelled the end to the pharmaceutical blockbuster model, pundits say. Japan’s drug review trend of late surveyed by Jiho corroborates this observation. Jiho...read more